- 75% of people with a mental health problem develop it before the age of 24
- Treatments for depression in under-18s are effective in only 60% of cases
- Depression arises from a complex set of factors
Aviva is supporting a project led by The Foundation for Young People’s Mental Health (YPMH) and researchers at Cambridge University exploring new methods of prevention, early intervention, diagnosis and treatment of depression in young people.
The first two years of the project have culminated in the release of the major report Changing Hearts, Changing Minds1 from YPMH in collaboration with the University of Cambridge’s Institute for Manufacturing (IfM) and IfM Engage.2
Around 322 million people globally suffer from depression and its prevalence is increasing, particularly among the young.3 Some 75% of people with a mental health problem develop it before the age of 24, and 50% develop it before the age of 14.4
Current treatments for depression in under-18s are effective in only 60% of cases. Between 50% and 75% experience a relapse, even after successful treatment.5
The report has joined up different areas of research into depression amongst young people and used IfM’s innovation methods to explore new approaches to prevention, early intervention, diagnosis and treatment of depression in young people.
Changing Hearts, Changing Minds also explains that depression is not “all in the mind” but arises from a complex set of factors across someone’s life, including:
- Our body’s biological systems, in particular, our nervous, endocrine and immune systems; our gut health; our genes and how they are turned on or off.
- Any underlying health conditions that we might have.
- Our choices and actions regarding diet, exercise, sleep, and substance use.
- Our economic, emotional, social, community and physical environments.
- Psychological factors such as our perceptions of stress and the effectiveness of our coping strategies.
- Adverse changes to the body during critical life stages from in utero to young adulthood.
Using these factors, the report identifies interventions that aim to prevent the development of first-episode depression, help people recover from depression or prevent the recurrence of depression.
The second phase of the project, funded by the Aviva foundation, will build on the findings of the Changing Hearts, Changing Minds report to further understand how depression develops, particularly in young people aged up to 25, and identify what needs to be done to translate the ideas for interventions into practice.
The work will be conducted by Dr Olivia Remes with consultation from YPMH and collaborative workshops with key stakeholders across the mental health sector.
The next phase will focus on how the interventions can be applied in three key areas:
- Self-care by individuals and their families
- The healthcare system
- Wider mental health support e.g. from schools, employers and mental health support charities
The project has a strong alignment to Aviva’s purpose ‘With you today, for a better tomorrow’ by focusing on early intervention for individuals to improve their future health and wellbeing outcomes.
Dr Doug Wright, medical director of Aviva UK Health, said: “Members of Aviva’s clinical and innovation teams have participated in the project described in Changing Hearts, Changing Minds, which clearly identifies novel approaches to understanding and addressing depression as it develops in young people.
“Aviva is keen to see these exciting ideas translated into real solutions and healthcare policy to help those young people who are suffering, their families and carers. Aviva is supporting the follow-on project to help fast-track the development and adoption of the most promising ideas.”
Professor Peter Jones, professor in the Department of Psychiatry at the University of Cambridge and chair of the project steering group, said: “More young people than ever are suffering from depression, but treatments have changed little in the last 30 years. This project has resulted in a better understanding of the complex pathways that connect an individual’s environment, diet, exercise, sleep, use of substances and underlying health conditions with their biological systems – and how all of these factors have a part to play in the development of depression.”
Peter Templeton, executive director of strategic development at IfM Engage and founder of YPMH, said: “I hope that this project will, indeed, change hearts and minds and lead to new approaches to the prevention, early diagnosis and treatment of depression in young people, and that these new approaches will lead to improved mental health outcomes for young people and their families. I sincerely hope that this project will be the pebble at the top of a mountain that causes an avalanche of positive change.”
Protection, Health and Regulation
About the Aviva-Cambridge partnership
Aviva PLC has been a strategic partner of the University of Cambridge since 2018. Through the partnership, the two organisations collaborate on research, education and training with the shared aim of achieving positive societal impact.
About the Institute for Manufacturing (IfM)
Part of the University of Cambridge’s Department of Engineering, the IfM is a dynamic body of researchers, educators, practitioners, professionals and technical experts contributing to world-leading research and education. With a focus on manufacturing industries, the IfM creates, develops and deploys new insights into management, technology and policy.
About the Foundation for Young People’s Mental Health
The William Templeton Foundation for Young People’s Mental Health (YPMH) is a charitable foundation working to improve the lives of young people by facilitating innovative approaches to resolve mental health conditions.
YPMH was established in memory of Will Templeton, by his parents Anne and Peter and his brother John. The family’s aspiration is to enable the ‘joining-up’ of excellent research and practice across the many fields associated with young people’s mental health to improve the prevention, identification, diagnosis and treatment of conditions such as depression and anxiety.
 IfM Engage is a Cambridge University-owned company that applies IfM research to help companies, governments and academia around the world.
 Aviva/Cambridge partnership report
 Changing Hearts, Changing Minds
 Changing Hearts, Changing Minds
Notes to editors:
- We are one of the UK’s leading Insurance, Wealth & Retirement businesses and we operate in the UK, Ireland and Canada. We also have international investments in India, China and Singapore.
- We help our 18.7 million customers make the most out of life, plan for the future, and have the confidence that if things go wrong we’ll be there to put it right.
- We have been taking care of people for more than 325 years, in line with our purpose of being ‘with you today, for a better tomorrow’. In 2022, we paid £23.2 billion in claims and benefits to our customers.
- Aviva is a market leader in sustainability. In 2021, we announced our plan to become Net Zero by 2040, the first major insurance company in the world to do so. This plan means Net Zero carbon emissions from our investments by 2040; setting out a clear pathway to get there with a cut of 25% in the carbon intensity of our investments by 2025 and of 60% by 2030; and Net Zero carbon emissions from our own operations and supply chain by 2030. Find out more about our climate goals at www.aviva.com/climate-goals and our sustainability ambition and action at www.aviva.com/sustainability
- While we are working towards our sustainability ambitions, we acknowledge that we have relationships with businesses and existing assets that may be associated with significant emissions. More information can be found at www.aviva.com/sustainability/climate/
- Aviva is a Living Wage and Living Hours employer and provides market-leading benefits for our people, including flexible working, paid carers leave and equal parental leave. Find out more at https://www.aviva.com/about-us/our-people/
- As at 31 December 2022, total Group assets under management at Aviva Group were £352 billion and our estimated Solvency II shareholder surplus is £8.7 billion. Our shares are listed on the London Stock Exchange and we are a member of the FTSE 100 index.
- For more details on what we do, our business and how we help our customers, visit www.aviva.com/about-us
- The Aviva newsroom at www.aviva.com/newsroom includes links to our spokespeople images, podcasts, research reports and our news release archive. Sign up to get the latest news from Aviva by email.
- You can follow us on:
- Twitter: www.twitter.com/avivaplc/
- LinkedIn: www.linkedin.com/company/aviva-plc
- Instagram: www.instagram.com/avivaplc
- For the latest corporate films from around our business, subscribe to our YouTube channel: www.youtube.com/user/aviva